LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 69.84 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 10.32K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 59.52K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 9.45K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-05-25 was 79.51K shares.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 155.19K shares, a 269.64% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 41.98K shares, a 32.17% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 61.90K shares, a 69.91% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 205.75K shares, a 61.10% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 10.32K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 69.84K shares 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | 59.52K shares 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | 31.29K shares 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | 9.45K shares 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | 79.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-07 | 124.70K shares derived: sum of 2 quarters · filed 2025-08-07 | 138.23K shares derived: sum of 3 quarters · filed 2025-08-07 | 155.19K shares 10-K · filed 2025-08-07 | |
| 2025-02-23 | 45.19K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-04-03 | 58.72K shares derived: sum of 2 quarters · filed 2025-04-03 | 75.68K shares 10-Q · filed 2025-04-03 | ||
| 2024-11-24 | 13.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-01-02 | 30.49K shares 10-Q · filed 2025-01-02 | |||
| 2024-08-25 | 16.96K shares 10-Q · filed 2024-10-04 | ||||
| 2024-05-26 | 41.98K shares 10-K · filed 2024-08-26 | ||||
| 2023-11-26 | 0.00 shares 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | 61.90K shares 10-K · filed 2024-03-20 | ||||
| 2022-05-29 | 205.75K shares 10-K · filed 2024-03-20 | ||||
| 2021-05-30 | 127.71K shares 10-K · filed 2024-03-20 | ||||
| 2020-05-31 | 55.81K shares 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | 71.67K shares 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | 23.33K shares 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |